Market capitalization | $3.51m |
Enterprise Value | $-30.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.00 |
EV/Sales (TTM) EV/Sales | -0.01 |
P/S ratio (TTM) P/S ratio | 0.67 |
P/B ratio (TTM) P/B ratio | 0.91 |
Revenue growth (TTM) Revenue growth | 133.58% |
Revenue (TTM) Revenue | $5.21m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
1 Analyst has issued a forecast Ensysce Biosciences Inc:
1 Analyst has issued a forecast Ensysce Biosciences Inc:
Dec '24 |
+/-
%
|
||
Revenue | 5.21 5.21 |
134%
134%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -6.73 -6.73 |
37%
37%
|
EBIT (Operating Income) EBIT | -6.73 -6.73 |
37%
37%
|
Net Profit | -7.99 -7.99 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.
Head office | United States |
CEO | D. Kirkpatrick |
Employees | 9 |
Founded | 2003 |
Website | www.ensysce.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.